Ruben Karapetian

RUBEN KARAPETIAN, Ph.D.

RUBEN KARAPETIAN, Ph.D.

A professional with 9+ years of industrial experience in drug discovery and development. Dr. R. Karapetian graduated from Moscow State University in 1998 and obtained his Ph.D. from the Institute of Physico-Chemical Biology, Moscow State University in 2001. During his Ph.D. work he was also a guest-scientist at Max-Planck Institute of Molecular Genetic in Berlin, Germany. His research is published in several peer-reviewed scientific papers in international and Russian academic journals and presented at domestic and international conferences.
Dr. Karapetian joined Chemical Diversity Research Institute in 2004. As the Head of Lead Discovery Department the last 5 years Dr. Karapetian is responsible for the execution of early discovery projects, and the design and management of preclinical development of innovative and generic drugs for registration in Russia. Under his supervision as the CSO of Avionco Ltd. He has successfully managed preclinical development of a novel and effective antiandrogen for the treatment of castration-resistant prostate cancer that is now in clinical development.